IRIDEX Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

IRIDEX wird ein Gewinn- und Umsatzwachstum von 47% bzw. 2.7% pro Jahr prognostiziert, während der Gewinn pro Aktie um 48.2% pro Jahr wachsen soll.

Wichtige Informationen

47.0%

Wachstumsrate der Gewinne

48.2%

EPS-Wachstumsrate

Medical Equipment Gewinnwachstum	16.7%
Wachstumsrate der Einnahmen	2.7%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	14 May 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Revenues Working Against IRIDEX Corporation's (NASDAQ:IRIX) Share Price Following 26% Dive

Jun 11

Lacklustre Performance Is Driving IRIDEX Corporation's (NASDAQ:IRIX) 32% Price Drop

Aug 12

Will IRIDEX (NASDAQ:IRIX) Spend Its Cash Wisely?

Apr 14

We're Hopeful That IRIDEX (NASDAQ:IRIX) Will Use Its Cash Wisely

Oct 12

Is IRIDEX (NASDAQ:IRIX) Using Too Much Debt?

Feb 25

Iridex To Benefit From New Revolutionary Glaucoma Treatment

Jan 11

Analysts Expect Breakeven For IRIDEX Corporation (NASDAQ:IRIX) Before Long

Jan 03

IRIDEX says laser therapy now accepted in the European Glaucoma Society guidelines

Dec 23

Gewinn- und Umsatzwachstumsprognosen

NasdaqGM:IRIX - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2025	52	-4	N/A	N/A	1
12/31/2024	50	-8	N/A	N/A	1
3/30/2024	50	-11	-6	-6	N/A
12/30/2023	52	-10	-7	-7	N/A
9/30/2023	55	-8	-8	-7	N/A
7/1/2023	56	-8	-8	-8	N/A
4/1/2023	57	-7	-9	-9	N/A
12/31/2022	57	-8	-10	-10	N/A
10/1/2022	57	-9	-10	-10	N/A
7/2/2022	56	-9	-8	-8	N/A
4/2/2022	55	-6	-7	-7	N/A
1/1/2022	54	-5	8	8	N/A
10/2/2021	51	-3	10	10	N/A
7/3/2021	46	-3	11	11	N/A
4/3/2021	39	-7	10	10	N/A
1/2/2021	36	-6	-3	-3	N/A
9/26/2020	36	-8	-3	-3	N/A
6/27/2020	38	-8	-6	-6	N/A
3/28/2020	42	-7	-6	-6	N/A
12/28/2019	43	-9	-8	-8	N/A
9/28/2019	43	-10	-10	-10	N/A
6/29/2019	44	-11	-10	-10	N/A
3/30/2019	44	-12	-11	-11	N/A
12/29/2018	43	-13	-10	-10	N/A
9/29/2018	41	-15	-9	-9	N/A
6/30/2018	41	-15	-8	-8	N/A
3/31/2018	41	-15	-5	-5	N/A
12/30/2017	42	-13	N/A	-4	N/A
9/30/2017	44	-19	N/A	-3	N/A
7/1/2017	43	-16	N/A	-3	N/A
4/1/2017	45	-14	N/A	-2	N/A
12/31/2016	46	-12	N/A	0	N/A
10/1/2016	46	0	N/A	0	N/A
7/2/2016	46	1	N/A	1	N/A
4/2/2016	43	0	N/A	-1	N/A
1/2/2016	42	0	N/A	-1	N/A
10/3/2015	41	9	N/A	1	N/A
7/4/2015	42	9	N/A	3	N/A
4/4/2015	43	10	N/A	4	N/A
1/3/2015	43	10	N/A	4	N/A
9/27/2014	42	2	N/A	2	N/A
6/28/2014	41	2	N/A	2	N/A
3/29/2014	40	2	N/A	2	N/A
12/28/2013	38	2	N/A	1	N/A
9/28/2013	37	2	N/A	2	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: IRIX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: IRIX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: IRIX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: IRIXDie Einnahmen des Unternehmens (2.7% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (8.7% pro Jahr).

Hohe Wachstumseinnahmen: IRIXDie Einnahmen des Unternehmens (2.7% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von IRIX in 3 Jahren voraussichtlich hoch sein wird

IRIDEX Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates fall by 32%

Price target decreased by 48% to US$2.00

Consensus EPS estimates fall by 35%

IRIDEX Corporation Provides Revenue Guidance for the Year 2023

IRIDEX Corporation Reiterates Financial Guidance for 2023

Consensus EPS estimates fall by 13%

Recent updates

IRIDEX Corporation Announces Composition of Audit Committee

Revenues Working Against IRIDEX Corporation's (NASDAQ:IRIX) Share Price Following 26% Dive

IRIDEX Corporation Appoints Patrick Mercer as Its President

Consensus EPS estimates fall by 32%

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Is IRIDEX (NASDAQ:IRIX) In A Good Position To Invest In Growth?

IRIDEX Corporation to Report Q1, 2024 Results on May 14, 2024

IRIDEX Corporation, Annual General Meeting, Jun 18, 2024

Iridex's Strategic Review Process Should Bear Fruit 'Soon'

Full year 2023 earnings: EPS and revenues miss analyst expectations

IRIDEX Corporation to Report Q4, 2023 Results on Mar 26, 2024

Little Excitement Around IRIDEX Corporation's (NASDAQ:IRIX) Revenues

Price target decreased by 48% to US$2.00

Iridex Corporation Announces First Patient Enrollment in MicroPulse® TLT Clinical Study Conducted in Collaboration with Imperial College Healthcare NHS Trust

Iridex Corporation Launches New Iridex 532 and Iridex 577 Lasers in US Market Marking 35 Years of Laser Innovation in Treating Retina Disorders & Glaucoma

Iridex Corporation Announces Successful Appeal for Revision of Recent Medicare LCDs to Provide Broader Coverage of Cyclophotocoagulation

Iridex Corporation Announces Successful Appeal for Revision of Recent Medicare LCDs to Provide Broader Coverage of Cyclophotocoagulation

IRIDEX Corporation announced delayed 10-Q filing

IRIDEX Corporation announced delayed 10-Q filing

New major risk - Share price stability

IRIDEX Corporation to Report Q3, 2023 Results on Nov 14, 2023

Will IRIDEX (NASDAQ:IRIX) Spend Its Cash Wisely?

Consensus EPS estimates fall by 35%

New minor risk - Share price stability

Lacklustre Performance Is Driving IRIDEX Corporation's (NASDAQ:IRIX) 32% Price Drop

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

IRIDEX Corporation Provides Revenue Guidance for the Year 2023

IRIDEX Corporation to Report Q2, 2023 Results on Aug 10, 2023

First quarter 2023 earnings: EPS misses analyst expectations

IRIDEX Corporation Reiterates Financial Guidance for 2023

Will IRIDEX (NASDAQ:IRIX) Spend Its Cash Wisely?

Consensus EPS estimates fall by 13%

Full year 2022 earnings: EPS exceeds analyst expectations

IRIDEX Corporation Provides Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2022

Price target decreased to US$5.63

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

IRIDEX Corporation Provides Revenue Guidance for the Year 2022

IRIDEX Corporation to Report Q3, 2022 Results on Nov 10, 2022

We're Hopeful That IRIDEX (NASDAQ:IRIX) Will Use Its Cash Wisely

Iridex Corporation Showcases its Non-Incisional Treatments for Glaucoma and Introduces Sweep Management Software at AAO 2022

IRIDEX Corporation Revises Revenue Guidance for the Full Year 2022

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

IRIDEX Corporation to Report Q2, 2022 Results on Aug 15, 2022

IRIDEX Corporation Obtains Regulatory Clearance for Cyclo G6(R) Glaucoma Platform in China

IRIDEX Corporation Provides Revenue Guidance for the Full Year 2022

First quarter 2022 earnings: EPS exceeds analyst expectations

Price target increased to US$9.75

Iridex Corporation Modifies the Composition of its Audit Committee, Compensation Committee, and Nominating and Governance Committee

Consensus EPS estimates fall by 62%

Full year 2021 earnings: EPS and revenues exceed analyst expectations

IRIDEX Corporation to Report Q4, 2021 Results on Mar 10, 2022

Third quarter 2021 earnings released: US$0.14 loss per share (vs US$0.12 loss in 3Q 2020)

Second quarter 2021 earnings released: EPS US$0.089 (vs US$0.20 loss in 2Q 2020)

Iridex Corporation Revises Earnings Guidance for the Year 2021

No longer forecast to breakeven

Price target increased to US$10.50

IRIDEX Corporation Provides Earnings Guidance for the Fiscal Year 2021

Iridex Corporation Announces It Cannot Provide Meaningful Financial Guidance for 2021

IRIDEX Corporation announced that it has received $10 million in funding from Topcon America Corporation

IRIDEX Corporation to Report Q4, 2020 Results on Mar 22, 2021

IRIDEX Corporation (NasdaqGM:IRIX) entered into an asset purchase agreement to acquire substantially all the assets from Topcon Medical Laser Systems Inc.

Is IRIDEX (NASDAQ:IRIX) Using Too Much Debt?

New 90-day high: US$5.82

Price target raised to US$6.50

New 90-day high: US$4.13

Iridex To Benefit From New Revolutionary Glaucoma Treatment

Analysts Expect Breakeven For IRIDEX Corporation (NASDAQ:IRIX) Before Long

IRIDEX says laser therapy now accepted in the European Glaucoma Society guidelines

New 90-day low: US$1.66